Back to news

Will chronic wounds have a better treatment? SolasCure, a new company in Hovione Capital’s portfolio.

31 . Aug . 2018
Share:
Linkedin
Today, we announce a new portfolio company: SolasCure, developing a disruptive technology for wound debridement, a therapeutic procedure where dead, damaged, or infected tissue is removed to improve wound healing.

There are more than 40 million patients worldwide suffering from painful and ineffective debridement procedures. SolasCure is developing a novel hydrogel containing a safe, and highly specific, enzyme that can potentially allow more effective debridement of chronic wounds. The primary standard of care for cleaning wounds is surgical or autolytic debridement. Surgical debridement is rapid and efficient but invasive and requires costly, highly-trained personnel. Autolytic debridement typically needs weeks to months to complete wound cleaning.

This project is a spin-off from BRAIN, a German Biotech company. SolasCure counts with a very experienced team: Dr. Sam Bakri, Chairman, a serial entrepreneur, prior CEO and co-founder of Kind Consumer, co-founder of AIDA Health with several years of work in medical technology companies; Dr. David Goldsmith, Chief Medical Officer, is a kidney doctor, with several academic positions in London and Europe, has written over 500 books, reviews, articles and other publications; Dr. Bela Kelety, Chief Technology Officer, head of New Business Development at BRAIN and a PhD from Max Planck Institute; Benjamin Newmark, Chief Financial Officer, with multiple leadership roles across several startups in healthcare; and Lily Bouzelmat, Operations Director, biologist, that led global Phase I to III clinical studies in various therapeutic areas in the US. 

SolasCure secured investment from Hovione Capital, the Development Bank of Wales (Welsh governmental organization that supports the economy of the region), and other investors.
Your cookie settings

We ask you to accept cookies for the purpose of performance, social networking and advertising.
For more information or correct your preferences, press the button "more info".
For more information about these cookies and the processing of your personal data, check out our cookie and Privacy Policy. Accept these cookies and the processing of personal data involved?

Accept cookies More information